National Institute for Health and Care Excellence4d
Vibostolimab–pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID6382]
The Department of Health has asked NICE to produce guidance on using the above technology in the NHS in England. The company has informed NICE that it will not provide an evidence submission for this ...
National Institute for Health and Care Excellence4d
Pembrolizumab–vibostolimab for untreated metastatic non-small-cell lung cancer [ID6365]
The Department of Health has asked NICE to produce guidance on using the above technology in the NHS in England. The company has informed NICE that it will not provide an evidence submission for this ...
National Institute for Health and Care Excellence19d
Tirzepatide for managing overweight and obesity
Tirzepatide's gastrointestinal adverse effects could lead to dehydration and in turn a deterioration in renal function including acute renal failure. Older people and some other groups of people may ...
National Institute for Health and Care Excellence19d
Tirzepatide for managing overweight and obesity
Tirzepatide should be thought about as an option for individual people in line with NICE's guideline on overweight and obesity management. The visual summary care pathway has an overview. Table 4 is ...
National Institute for Health and Care Excellence19d
Tirzepatide for managing overweight and obesity
NICE has produced a resource impact assessment tool for tirzepatide. NICE estimates that the total eligible population is 3.4 million people, and expects that an interim NHS England commissioning ...
National Institute for Health and Care Excellence20d
Tirzepatide for managing overweight and obesity
The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to ...
National Institute for Health and Care Excellence20d
Tirzepatide for managing overweight and obesity
Tirzepatide is recommended as an option for managing overweight and obesity, alongside a reduced-calorie diet and increased physical activity in adults, only if they have: an initial body mass index ...
National Institute for Health and Care Excellence20d
Tirzepatide for managing overweight and obesity
Tirzepatide (Mounjaro, Eli Lilly) is a long-acting dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide‑1 (GLP‑1) receptor agonist for subcutaneous injection with a ...
National Institute for Health and Care Excellence20d
Tirzepatide for managing overweight and obesity
The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee A. Committee members are asked to declare any interests in the technology being ...
National Institute for Health and Care Excellence20d
Tirzepatide for managing overweight and obesity
NICE's medicines practice guideline on developing and updating local formularies recommends that medicines recommended in NICE technology appraisals are adopted into local formularies automatically ...
National Institute for Health and Care Excellence20d
Tirzepatide for managing overweight and obesity
In SURMOUNT‑1 and SURMOUNT‑2, 2,519 people had tirzepatide alone or in combination with other glucose-lowering medicines. The most frequently reported adverse reactions were gastrointestinal disorders ...